Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Sangamo Therapeutics宣佈輝瑞的Giroctocogene Fitelparvovec三期試驗達到主要和關鍵次要目標；如果獲批並商業化，可獲得高達2.2億美元的里程碑支付和14%-20%的版稅。
Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Sangamo Therapeutics宣佈輝瑞的Giroctocogene Fitelparvovec三期試驗達到主要和關鍵次要目標；如果獲批並商業化，可獲得高達2.2億美元的里程碑支付和14%-20%的版稅。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。